Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIC-TAC-SAM
2024-511807-41-00Phase 3Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of etoposide in haemophagocytic lymphohistiocytosis (HLH) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite organ failure event. Planned start Mar 2025; status: withdrawn.
02
Drugs
etoposide
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2024-511807-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511807-41-00.